RBC
CPRX

Roble Belko & Company’s Catalyst Pharmaceutical CPRX Stock Holding History

Roble Belko & Company’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-200
Closed -$3K – 298
2023
Q2 		$3K Buy
+200
New +$2.88K ﹤0.01% 250

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Roble Belko & Company's CPRX Position: Q3 2023 in Review

Roble Belko & Company sold out of Catalyst Pharmaceutical (CPRX) in Q3 2023, closing a stake of 200 shares — an estimated $3K sold.

Roble Belko & Company first reported a position in CPRX in Q2 2023 and held it in 1 quarter. The position peaked at $3K in Q2 2023. 255 funds tracked by Wall St. Rank hold CPRX as of Q3 2023.

  • Roble Belko & Company reported no remaining Catalyst Pharmaceutical position as of Q3 2023 after selling out during the quarter.
  • Roble Belko & Company sold 200 Catalyst Pharmaceutical shares in Q3 2023, an estimated $3K.
  • Roble Belko & Company first reported a position in Catalyst Pharmaceutical in Q2 2023 and held it in 1 quarter.
  • Roble Belko & Company's Catalyst Pharmaceutical position peaked at $3K in Q2 2023.
  • 255 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2023.

Based on Roble Belko & Company's 13F filing for Q3 2023, filed 1 Nov 2023.